NCT04180865|UnknownDMC
The Dutch Parkinson and Cognition Study
DUPARC
Loading search results
DUPARC
Sponsor study identifier
Secondary identifiers
REGISTRY · Centrale Commissie Mensgebonden Onderzoek (CCMO)
observational
150
1 country
1
Study Start
October 1, 2017
Actual (reported)Primary Completion
October 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
October 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Parkinson Disease (PD) is a heterogeneous, progressive neurodegenerative disorder which is characterized by a variety of motor and non-motor symptoms. The DUPARC study is a single-centre longitudinal cohort study aimed at deeply phenotyping newly diagnosed PD patients. The main aim is to investigate the relationship between cognitive impairment and both cholinergic and dopaminergic neurodegeneration in the early stages of the disease. In addition, gastrointestinal and visual system dysfunction in PD and their role in the underlying pathology are further explored in a longitudinal setup. Treatment-naïve participants will undergo extensive motor- and non-motor assessment, imaging, and microbiome assessment at time of diagnosis, and will be followed for at least 3 years.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 1, 2017
Actual (reported)November 4, 2019
Actual (reported)November 29, 2019
Actual (reported)October 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
October 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
[18F]FEOBV PET
Cortical and subcortical cholinergic innervation as measured by \[18F\] FEOBV PET imaging
Baseline
Cognitive screening
baseline
Memory performance
baseline
Attention and working memory performance
baseline
Executive function performance
baseline
Visouspatial abilities
baseline
Hospital Anxiety and Depression Scale
Baseline, 1 year follow-up, 3 year follow-up
Utrechtse Coping Lijst
Baseline, 1 year follow-up, 3 year follow-up
The Dysexecutive Questionnaire
Baseline, 1 year follow-up, 3 year follow-up
150 de novo treatment naive Parkinson's disease patients.
150 Healthy sex- and age-matched controls, also matched according to presence and severity of constipation, serving as a control group for microbiome composition analyses.
150 PD patients who are treatment naïve at baseline, diagnosed by a movement disorders specialist, based on the Movement Disorder Society Clinical Diagnostic Criteria for PD. Patients are recruited at partnering hospitals in the northern part of the Netherlands
University Medical Center Groningen
Groningen, 9700RB, Netherlands
Chrysou A, Heikka T, van der Zee S, Boertien JM, Jansonius NM, van Laar T. Reduced Thickness of the Retina in de novo Parkinson's Disease Shows A Distinct Pattern, Different from Glaucoma. J Parkinsons Dis. 2024;14(3):507-519. doi: 10.3233/JPD-223481.
Boertien JM, van der Zee S, Chrysou A, Gerritsen MJJ, Jansonius NM, Spikman JM, van Laar T; PPNN Study Group. Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson's disease patients for the identification and validation of biomarkers for Parkinson's disease subtypes, progression and pathophysiology. BMC Neurol. 2020 Jun 13;20(1):245. doi: 10.1186/s12883-020-01811-3.
Feces; Saliva; Plasma EDTA; Buffy coat (plasma EDTA); Serum;
Teus van Laar, MD PhD
University Medical Center Groningen
First Submitted
November 4, 2019
First Posted
November 29, 2019
Study Start
October 1, 2017
Actual (reported)Primary Completion
October 1, 2023
Estimated (date passed)Real-PD Trial: Development of Clinical Prognostic Models for Parkinson's Disease
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
October 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
November 29, 2019
Record last verified: 2019-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: